MedTrace Logo

REtinal and VIsual Cortical Response in Early PSYchosis

NCT05167396 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-08-22

No results posted yet for this study

Summary

The purpose of the REVIPSY study is to measure retinal and the visual cortical electrophysiological responses in situations at risk of psychosis in patients who have experienced a first psychotic episode. A perspective of this project will be to create new electrophysiological biomarkers predictive of the risk of conversion to psychosis

Conditions

  • Prodromal Schizophrenia
  • Psychotic Episode
  • Prodromal Symptoms
  • Healthy Controls

Interventions

DEVICE

Retinaute (BioSerenity)

Wearable device in the form of a virtual reality headset for the recording of electrophysiological measurements such as electroretinogram (ERG) and electrocenphalogram (EEG), ISCEV standards

DEVICE

EEG Headset 64 electrodes (BioSemi)

EEG headset with 64 electrodes for the recording of visual cortical electrophysiological signals

DEVICE

MonPackOne (Metrovision)

Standard device for the recording of electroretinography (ERG) measurements, ISCEV standards WARNING : Device used only in 3 healthy controls to address the secondary objective

Sponsors & Collaborators

  • BioSerenity

    collaborator INDUSTRY

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Centre Psychothérapique de Nancy

    lead OTHER

Principal Investigators

  • Vincent LAPRÉVOTE, Pr. MD PhD · Centre Psychothérapique de Nancy

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-26
Primary Completion
2023-07-20
Completion
2023-07-20

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05167396 on ClinicalTrials.gov